Estimating prostate cancer size can help clinicians more accurately make informed treatment decisions. Researchers have trained and validated an AI model for doing this accurately and consistently, based on MRI scans from more than 700 prostate cancer patients. The model was able to identify and demarcate the edges of 85% of the most radiologically aggressive prostate lesions. Tumours with a larger volume as estimated by the AI model were associated with a higher risk of treatment failure and metastasis, independent of other factors  normally used to estimate risk.

Read the full article in Radiology here.

An Australian urologist, Samantha Pillay, has created a short film titled “Just say PSA” using artificial intelligence to raise awareness about prostate cancer and encourage men to have vital conversations with their doctors about PSA screening.

A study form Umea University in Sweden investigated the role that a protein may play in the fight against certain types of prostate cancer. Activating the protein GP130, which acts as a receptor on the surface of cells, not only slows tumour growth but stimulates the immune system to actively fight tumour cells.

High levels of GP130 correlated positively with improved survival, say the authors. In the long term, this may open up the possibility of a new treatment option for mainly certain types of aggressive prostate cancer that are currently difficult to treat.

A new article published in European Urology Oncology highlights the effectiveness of the Stockholm3 blood test in repeat screening for prostate cancer. The clinical study demonstrated that using Stockholm3 instead of traditional prostate-specific antigen (PSA) testing increased detection of clinically significant cancers by 31%, without increasing the need for magnetic resonance imaging.

Please complete our EU-PRESS shared decision making survey, available in 17 languages, by 31st December. https://eupress.eu/.

The European Cancer Organisation wants to raise awareness of two projects:

smartCARE is a EU4Health project developing a cancer survivor smart card – in the form of a mobile app – to improve the health and wellbeing of cancer survivors throughout Europe. Learn more about the project here and watch the video here.

In November, Active Surveillance Patients International (ASPI) held a Zoom webinar on “How you can help in clinical research on active surveillance”. You can watch the recording of this meeting here.